These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 31360079)

  • 1. Managing treatment-related peripheral neuropathy in patients with multiple myeloma.
    Grammatico S; Cesini L; Petrucci MT
    Blood Lymphat Cancer; 2016; 6():37-47. PubMed ID: 31360079
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of treatment-emergent peripheral neuropathy in multiple myeloma.
    Richardson PG; Delforge M; Beksac M; Wen P; Jongen JL; Sezer O; Terpos E; Munshi N; Palumbo A; Rajkumar SV; Harousseau JL; Moreau P; Avet-Loiseau H; Lee JH; Cavo M; Merlini G; Voorhees P; Chng WJ; Mazumder A; Usmani S; Einsele H; Comenzo R; Orlowski R; Vesole D; Lahuerta JJ; Niesvizky R; Siegel D; Mateos MV; Dimopoulos M; Lonial S; Jagannath S; Bladé J; Miguel JS; Morgan G; Anderson KC; Durie BG; Sonneveld P
    Leukemia; 2012 Apr; 26(4):595-608. PubMed ID: 22193964
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peripheral neuropathy and new treatments for multiple myeloma: background and practical recommendations.
    Mohty B; El-Cheikh J; Yakoub-Agha I; Moreau P; Harousseau JL; Mohty M
    Haematologica; 2010 Feb; 95(2):311-9. PubMed ID: 20139393
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of multiple myeloma: thalidomide-, bortezomib-, and lenalidomide-induced peripheral neuropathy.
    Koeppen S
    Oncol Res Treat; 2014; 37(9):506-13. PubMed ID: 25231692
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bortezomib in multiple myeloma and lymphoma: a systematic review and clinical practice guideline.
    Reece D; Imrie K; Stevens A; Smith CA;
    Curr Oncol; 2006 Oct; 13(5):160-72. PubMed ID: 22792013
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature.
    Argyriou AA; Iconomou G; Kalofonos HP
    Blood; 2008 Sep; 112(5):1593-9. PubMed ID: 18574024
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vinca alkaloids, thalidomide and eribulin-induced peripheral neurotoxicity: From pathogenesis to treatment.
    Islam B; Lustberg M; Staff NP; Kolb N; Alberti P; Argyriou AA
    J Peripher Nerv Syst; 2019 Oct; 24 Suppl 2():S63-S73. PubMed ID: 31647152
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial.
    Broyl A; Corthals SL; Jongen JL; van der Holt B; Kuiper R; de Knegt Y; van Duin M; el Jarari L; Bertsch U; Lokhorst HM; Durie BG; Goldschmidt H; Sonneveld P
    Lancet Oncol; 2010 Nov; 11(11):1057-65. PubMed ID: 20864405
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bortezomib and other proteosome inhibitors-induced peripheral neurotoxicity: From pathogenesis to treatment.
    Velasco R; Alberti P; Bruna J; Psimaras D; Argyriou AA
    J Peripher Nerv Syst; 2019 Oct; 24 Suppl 2():S52-S62. PubMed ID: 31647153
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low serum vitamin D occurs commonly among multiple myeloma patients treated with bortezomib and/or thalidomide and is associated with severe neuropathy.
    Wang J; Udd KA; Vidisheva A; Swift RA; Spektor TM; Bravin E; Ibrahim E; Treisman J; Masri M; Berenson JR
    Support Care Cancer; 2016 Jul; 24(7):3105-10. PubMed ID: 26902977
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention of Bortezomib-Related Peripheral Neuropathy With Docosahexaenoic Acid and α-Lipoic Acid in Patients With Multiple Myeloma: Preliminary Data.
    Maschio M; Zarabla A; Maialetti A; Marchesi F; Giannarelli D; Gumenyuk S; Pisani F; Renzi D; Galiè E; Mengarelli A
    Integr Cancer Ther; 2018 Dec; 17(4):1115-1124. PubMed ID: 30295079
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence of Chemotherapy-Induced Peripheral Neuropathy in Multiple Myeloma Patients and its Impact on Quality of Life: A Single Center Cross-Sectional Study.
    Selvy M; Kerckhove N; Pereira B; Barreau F; Nguyen D; Busserolles J; Giraudet F; Cabrespine A; Chaleteix C; Soubrier M; Bay JO; Lemal R; Balayssac D
    Front Pharmacol; 2021; 12():637593. PubMed ID: 33967771
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of neuropathy in patients with myeloma treated with thalidomide: patterns of occurrence and the role of electrophysiologic monitoring.
    Mileshkin L; Stark R; Day B; Seymour JF; Zeldis JB; Prince HM
    J Clin Oncol; 2006 Sep; 24(27):4507-14. PubMed ID: 16940275
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Seropositive Neuromyelitis Optica in a Case of Undiagnosed Ankylosing Spondylitis: A Neuro-Rheumatological Conundrum.
    Ghosh Md R; Roy D; León-Ruiz M; Das S; Dubey S; Benito-León J
    Qatar Med J; 2022; 2022(3):29. PubMed ID: 35864917
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adhesive capsaicin 8% patch for improved control of pain caused by chemotherapy-induced peripheral neuropathy in patients with multiple myeloma: A single-centre, seven-case series.
    Moreno-Alonso D; Llorens-Torromé S; Corcoy de Febrer B; Amandi García M; Serrano-Bermúdez G; Trelis-Navarro J; Mayoral-Rojals V; Serrano-Afonso A
    J Oncol Pharm Pract; 2024 Jun; 30(4):752-758. PubMed ID: 38415287
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of the neuronal NFκB pathway attenuates bortezomib-induced neuropathy in a mouse model.
    Alé A; Bruna J; Calls A; Karamita M; Haralambous S; Probert L; Navarro X; Udina E
    Neurotoxicology; 2016 Jul; 55():58-64. PubMed ID: 27211850
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiple myeloma, painful neuropathy, acupuncture?
    Zhou Y; Garcia MK; Chang DZ; Chiang J; Lu J; Yi Q; Romaguera J; Delasalle K; Guo Y; Forman A; Fang W; Wang M
    Am J Clin Oncol; 2009 Jun; 32(3):319-25. PubMed ID: 19887992
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A multicenter retrospective analysis of adverse events in Korean patients using bortezomib for multiple myeloma.
    Bang SM; Lee JH; Yoon SS; Park S; Min CK; Kim CC; Suh C; Sohn SK; Min YH; Lee JJ; Kim K; Seong CM; Yoon HJ; Cho KS; Jo DY; Lee KH; Lee NR; Kim CS;
    Int J Hematol; 2006 May; 83(4):309-13. PubMed ID: 16757429
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature.
    Badros A; Goloubeva O; Dalal JS; Can I; Thompson J; Rapoport AP; Heyman M; Akpek G; Fenton RG
    Cancer; 2007 Sep; 110(5):1042-9. PubMed ID: 17654660
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peripheral neuropathy in hematologic malignancies - Past, present and future.
    Li T; Timmins HC; Lazarus HM; Park SB
    Blood Rev; 2020 Sep; 43():100653. PubMed ID: 31983507
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.